---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ANX007-GLA-01"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ANX007-GLA-01. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 26 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence/anx007-gla-01"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: ANX007-GLA-01

<a id="heading-3.1.5"></a>

## 3.1.5 ANX007-GLA-01

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Registered primary, secondary, and exploratory objectives of the phase 1a study

> “The primary objective is to evaluate the safety and tolerability of a single intravitreal (IVT) injection of ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate the serum pharmacokinetics (PK) and immunogenicity. An exploratory objective will evaluate the pharmacodynamic (PD) effect of ANX007 on serum C1q activity.”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="topic-3.1.5.1-2"></a>

#### Published objective of the first-in-human study

> “The phase Ia study was a first-in-human, open-label (no masking), dose-escalation safety study that evaluated 3 dose levels of ANX007 administered as single IVT injections (NCT03488550).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.1-3"></a>

#### Company statement of the objectives of the glaucoma studies

> “We completed single-ascending dose (n=9) and sham-controlled multiple dose (n=17) studies of intravitreal vonaprument in patients with glaucoma to evaluate safety, tolerability, pharmacokinetics and target engagement.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Registry dates for the phase 1a study

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2018-03-23” |
| Primary completion (actual) | “2018-08-03” |
| Study completion (actual) | “2018-08-03” |

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="topic-3.1.5.2-2"></a>

#### Phase 1a study site

> “The phase Ia study was conducted at a single site in the United States.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “Eye Research Foundation”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Registered design of the phase 1a study

> “A Phase 1, Open-label, Single-dose, Dose-escalation, Safety, Tolerability, and PK Study of Intravitreal ANX007 in Participants With Primary Open-angle Glaucoma”
> “This is a phase 1, open-label, dose-escalation, safety study evaluating up to 3 dose levels of ANX007 administered as single IVT injections.”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="topic-3.1.5.3-2"></a>

#### Dose escalation and dose-limiting toxicity criteria

> “In the dose-escalation phase Ia study, patients were enrolled into the lowest open cohort in an open-label manner and received a single dose of ANX007 at 1 of 3 dose levels (1 mg, 2.5 mg, or 5.0 mg), with cohort dose escalation in the absence of any dose-limiting toxicity. Dose-limiting toxicity criteria were defined as any of the following adverse events (AEs) occurring within 2 weeks after an IVT injection and considered to be related to ANX007: intraocular inflammation of at least grade 2, using the Standardization of Uveitis Nomenclature criteria, that was unresponsive to topical corticosteroid therapy; increase in IOP > 30 mm Hg that was unresponsive to topical or oral IOP-lowering medications; or loss of best corrected visual acuity of > 3 Snellen lines from baseline, excluding a transient loss immediately after IVT injection.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Published inclusion criteria for the phase 1a study

> “In the phase Ia study, eligible patients were aged ≥ 18 years, of either sex, with primary open-angle glaucoma on stable IOP-lowering medications, with a mean deviation of −3 to −18 dB on a reliable visual field test using the Humphrey field analyzer in the study eye, and an IOP < 21 mm Hg for ≥ 4 weeks before dosing, with no change to the IOP treatment regimen anticipated throughout study participation.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.4-2"></a>

#### Key exclusion criteria for both glaucoma studies

> “For both studies, key exclusion criteria included intraocular inflammatory or infectious eye disease; uncomplicated cataract surgery < 3 months before injection; trabeculectomy, iridotomy, vitrectomy, or other incisional ocular procedures in the study eye that could affect drug distribution and excretion; and history of autoimmune or neurologic disease.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.4-3"></a>

#### Registered exclusion criteria for the phase 1a study

> “BCVA worse than 20/80 in either eye”
> “Extensive glaucomatous visual-field damage”
> “History of uncomplicated cataract surgery less than 6 mos prior”
> “Previous tx with another humanized monoclonal antibody”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Single-dose cohorts

> “Nine patients with primary open-angle glaucoma (mean Humphrey visual field deviation between −3 and −18 decibels [dB]) were enrolled in phase Ia and received single doses of ANX007 (1.0 mg, n = 3; 2.5 mg, n = 3; or 5.0 mg, n = 3).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.5-2"></a>

#### Intravitreal injection procedure

> “Intravitreal injection was performed under sterile conditions. Topical proparacaine was used for anesthesia. Lid margins were cleaned with Povidone-iodine 10% and povidone-iodine 5% was applied to the conjunctival surface, including the injection site. For ANX007 injection, the needle was inserted perpendicular to the sclera, 3.5 to 4 mm posterior to the limbus, between the vertical and horizontal rectus muscles.”
> “Intraocular pressure was checked postinjection. Topical antibiotics were not used postinjection.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Adverse Events as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Registered outcomes of the phase 1a study

| Outcome | Time frame |
| --- | --- |
| “Safety and tolerability as measured by the occurrence of adverse events” | “Day 56” |
| “Serum plasma concentration of ANX007 after a single IVT injection.” | “Day 15” |
| “Immunogenicity of ANX007 after a single IVT injection.” | “Day 56” |
| “Effect of a single IVT injection of ANX007 on serum C1q” | “Day 15” |

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

<a id="topic-3.1.5.6.1-2"></a>

##### Follow-up and sampling in the phase 1a study

> “In the dose-escalation phase Ia study, patients were followed for a total of 8 weeks for safety, tolerability, PK (unbound ANX007 serum concentration)”
> “In the single-dose study, samples for PK and PD analyses were obtained preinjection and 3 hours postinjection on day 1, and on days 2, 4, 8, and 15. Samples for the evaluation of serum ADAs were obtained preinjection, on study day 29, and at the follow-up visit on day 56.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Planned and enrolled participants in the phase 1a study

> “Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.”

Source: [ClinicalTrials.gov NCT03488550](https://clinicaltrials.gov/study/NCT03488550)

> “Sample sizes were determined by clinical and practical, rather than statistical, considerations.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Safety and immunogenicity analysis population

> “Pooled data are reported by dose level of ANX007 by study and non-study eye, where applicable. Patients who received ≥ 1 injection of ANX007 were assessed for safety and immunogenicity endpoints. The incidences of treatment-emergent AEs were tabulated by system organ class and preferred term, as well as by ocular or systemic intensity, or Common Terminology Criteria for Adverse Events grade, and by relationship to ANX007.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Completion of the phase 1a study

> “All 9 patients completed the study; there were no early terminations.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Demographics of the phase 1a study by dose cohort

| Characteristic | ANX007 1.0 mg (n = 3) | ANX007 2.5 mg (n = 3) | ANX007 5.0 mg (n = 3) | Overall (n = 9) |
| --- | --- | --- | --- | --- |
| Age, mean (SD), yr | “66.3 (12.5)” | “70.7 (4.0)” | “72.7 (3.5)” | “69.9 (7.4)” |
| Age, median (min, max), yr | “66.0 (54, 79)” | “73.0 (66, 73)” | “73.0 (69, 76)” | “73.0 (54, 79)” |
| Male, n (%) | “1 (33.3)” | “3 (100.0)” | “2 (66.7)” | “6 (66.7)” |
| Female, n (%) | “2 (66.7)” | “0” | “1 (33.3)” | “3 (33.3)” |
| Black/African American, n (%) | “1 (33.3)” | “0” | “0” | “1 (11.1)” |
| Asian, n (%) | “0” | “2 (66.7)” | “0” | “2 (22.2)” |
| White, n (%) | “2 (66.7)” | “1 (33.3)” | “3 (100.0)” | “6 (66.7)” |
| Weight, mean (SD), kg | “105.2 (6.7)” | “83.7 (7.2)” | “82.2 (15.6)” | “90.3 (14.5)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.8.2-2"></a>

##### Overall phase 1a study population

> “The majority of patients were male (n = 6, 66.7%) and White (n = 6, 66.7%), with a mean age (SD) of 69.9 (7.4) years (Table 1).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Serum pharmacokinetics and C1q after a single dose

> “Serum unbound ANX007 was not detected, and serum unbound C1q levels were unchanged over the period of the study.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Adverse events in the phase 1a study by dose cohort

| n (%) | ANX007 1 mg (n = 3) | ANX007 2.5 mg (n = 3) | ANX007 5 mg (n = 3) | Overall (n = 9) |
| --- | --- | --- | --- | --- |
| Any TEAE | “3 (100.0)” | “3 (100.0)” | “3 (100.0)” | “9 (100.0)” |
| Ocular disorders | “3 (100.0)” | “3 (100.0)” | “2 (66.7)” | “8 (88.9)” |
| Infection | “0” | “0” | “1 (33.3)” | “1 (11.1)” |
| Treatment-related TEAE | “3 (100.0)” | “3 (100.0)” | “2 (66.7)” | “8 (88.9)” |
| Conjunctival hemorrhage | “0” | “2 (66.7)” | “0” | “2 (22.2)” |
| Conjunctival hyperemia | “3 (100.0)” | “3 (100.0)” | “2 (66.7)” | “8 (88.9)” |
| Eye irritation | “2 (66.7)” | “0” | “0” | “2 (22.2)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.8.5-2"></a>

##### Ocular and systemic adverse events after a single dose

> “Eight ocular TEAEs were reported in the study eye, including ocular irritation, conjunctival hemorrhage, and conjunctival hyperemia, and 1 systemic TEAE was reported (sinusitis) which was not assessed to be related to ANX007 (Table 2). No ocular TEAEs were reported in the non-study eye for any patient. All AEs were mild in severity and resolved by the end of the study and there were no clinically significant laboratory results at any time during the on-therapy period.”
> “No dose-limiting toxicities were observed.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.8.5-3"></a>

##### Safety across both glaucoma studies

> “In both studies, no serious adverse events were observed, no non-ocular treatment-emergent adverse events (TEAEs) attributable to study drug were reported, and ocular TEAEs were mild.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

> “The studies showed that vonaprument was well-tolerated at all doses (1 mg, 2.5 mg and 5 mg)”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-3.1.5.8.5-4"></a>

##### Intraocular pressure after a single dose

> “Intraocular pressure returned to normal levels (defined as within 5 mm Hg of baseline or ≤ 21 mm Hg) at 30 minutes for all patients. Mean IOP measurements were within normal limits (≤ 21 mm Hg) at all time points (Table 3).”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

| Time point | ANX007 1 mg, mean (SD) | ANX007 2.5 mg, mean (SD) | ANX007 5 mg, mean (SD) |
| --- | --- | --- | --- |
| Baseline | “17.7 (1.15)” | “16.3 (3.06)” | “15.0 (2.65)” |
| 30 minutes postinjection | “19.3 (2.89)” | “17.3 (4.16)” | “18.0 (3.61)” |
| Day 2 | “16.3 (3.79)” | “10.7 (3.06)” | “13.3 (2.52)” |
| Day 29 | “18.3 (1.53)” | “17.0 (1.00)” | “15.0 (5.29)” |
| Day 56 | “15.3 (1.15)” | “14.0 (1.00)” | “14.3 (3.21)” |

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-3.1.5.8.5-5"></a>

##### Anti-drug antibodies after a single dose

> “No ADAs positivity was detected during the study at any ANX007 dose level at any of the timepoints assessed.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary: glaucoma population, small open-label cohorts, and serum-only pharmacodynamics

ANX007-GLA-01 was a first-in-human, open-label, single-dose escalation study in 9 participants with primary open-angle glaucoma (3 per dose cohort of 1.0, 2.5, and 5.0 mg), a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. The study had no masking and no control arm, follow-up lasted 8 weeks, and sample sizes were “determined by clinical and practical, rather than statistical, considerations”, with data presented descriptively. Aqueous humor was not sampled in this study, so pharmacokinetics and target engagement were assessed in serum only, where unbound ANX007 was not detected. The article states that there were no treatment-emergent adverse events after single injections, and in the same paragraph reports 8 ocular treatment-emergent adverse events and 1 systemic event, with all 9 participants (100.0%) having any treatment-emergent adverse event in its Table 2. The 5-mg dose was given in 100 μL, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose.

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/); [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
